TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to “Sell” at Wall Street Zen

TuHURA Biosciences (NASDAQ:HURA) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

HURA has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, TuHURA Biosciences currently has a consensus rating of “Hold” and a consensus target price of $9.00.

TuHURA Biosciences Stock Up 8.4%

HURA opened at $1.94 on Friday. The company has a market capitalization of $117.80 million, a price-to-earnings ratio of -3.88 and a beta of -0.30. The firm has a 50-day moving average price of $1.18 and a 200-day moving average price of $1.68. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $4.44.

Institutional Investors Weigh In On TuHURA Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of HURA. Bank of America Corp DE bought a new position in shares of TuHURA Biosciences in the fourth quarter valued at approximately $59,000. Jane Street Group LLC bought a new stake in TuHURA Biosciences during the 1st quarter worth approximately $69,000. Geode Capital Management LLC increased its holdings in TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after acquiring an additional 307,260 shares during the period. Intech Investment Management LLC purchased a new stake in TuHURA Biosciences in the 2nd quarter worth approximately $29,000. Finally, JPMorgan Chase & Co. bought a new position in TuHURA Biosciences in the 2nd quarter valued at $27,000. 0.62% of the stock is currently owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.